aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Access Biotechnology, based in New York, is the life science investment arm of Access Industries. The company focuses on funding transformative therapies aimed at addressing conditions with high unmet medical needs. Their investments span both private and public biopharma companies, covering a wide range of therapeutic areas, modalities, and stages of development, from early discovery technologies to late-stage clinical programs.
Notable figures associated with Access Biotechnology include key leaders from Access Industries. The company has achieved significant milestones, such as backing startups that have rapidly advanced to clinical stages and facilitating acquisitions by major pharmaceutical companies like Novartis. Their impact is marked by the approval of groundbreaking drugs and fostering innovation in the biotech sector, ultimately contributing to advancements in human health.
Operating Status
Active
Ownership Type(s)
Private
Main Product(s)
Biotech Investing
Technology
Biotech
Tags
Biotech, Investing
Model Types
Financial
Revenue Type(s)
Financial
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Access Biotechnology founded?
Access Biotechnology was founded in 1986.
Where is Access Biotechnology's headquarters located?
Access Biotechnology's headquarters is located in New York City, NY, US.
How many employees does Access Biotechnology have?
Access Biotechnology has 8 employees as of Feb 4, 2024.
Add Comparison
Total Employees Over Time
8
As of Feb 2024
Access Biotechnology Address
New York City,
New York
11217
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts